Anika Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1996
Net Income	-82.67	-14.86	4.13	-23.98	27.19	18.72	31.82	32.55	30.76	38.32	Upgrade
Depreciation & Amortization	16.45	16.34	16.03	13.47	7.17	5.91	4.29	3.73	3.78	4.71	Upgrade
Share-Based Compensation	15.24	14.32	11.09	5.39	6.09	11.05	5.81	3.39	2.23	-8.02	Upgrade
Other Operating Activities	49.19	-11.38	-22.85	18.2	-3.45	-0.76	-1.1	-15.23	3.15	4.97	Upgrade
Operating Cash Flow	-1.79	4.41	8.4	13.07	37.01	34.92	40.81	24.45	39.91	39.98	Upgrade
Operating Cash Flow Growth	-	-47.49%	-35.73%	-64.69%	5.98%	-14.44%	66.93%	-38.74%	-0.17%	58.86%	Upgrade
Capital Expenditures	-5.43	-7.49	-5.14	-1.63	-2.83	-4.66	-8.98	-14.01	-9.23	-1.55	Upgrade
Acquisitions	0	0	-0.48	-94.6	0	0	0	0	0	0	Upgrade
Change in Investments	0	0	2.5	44.98	42.52	-45.6	-3.5	7.25	-21	-6.75	Upgrade
Other Investing Activities	-	-	-	-20.01	-	-	-	-	-	-	Upgrade
Investing Cash Flow	-5.43	-7.49	-3.12	-71.26	39.69	-50.26	-12.48	-6.76	-30.23	-8.3	Upgrade
Share Issuance / Repurchase	-4.17	0.68	1.13	1.52	-7.85	-27.11	0.31	-23.99	1.07	2.06	Upgrade
Debt Issued / Paid	0	-0.28	-0.2	-0.56	0	0	0	0	0	0	Upgrade
Other Financing Activities	-2.15	-5.25	-7.71	-4.74	-0.29	-1.79	-	-	-	3.28	Upgrade
Financing Cash Flow	-6.32	-4.85	-6.78	-3.77	-8.14	-28.9	0.31	-23.99	1.07	5.33	Upgrade
Exchange Rate Effect	0.08	-0.13	0.07	0.33	-0.13	0.03	0.35	-0.14	-0.21	-0.18	Upgrade
Net Cash Flow	-13.46	-8.06	-1.43	-61.65	68.42	-44.21	29	-6.45	10.55	36.82	Upgrade
Free Cash Flow	-7.22	-3.08	3.25	11.44	34.18	30.26	31.83	10.43	30.69	38.43	Upgrade
Free Cash Flow Growth	-	-	-71.55%	-66.54%	12.94%	-4.93%	205.08%	-66.00%	-20.14%	54.24%	Upgrade
Free Cash Flow Margin	-4.33%	-1.97%	2.20%	8.77%	29.82%	28.67%	28.07%	10.09%	33.00%	36.39%	Upgrade
Free Cash Flow Per Share	-0.49	-0.21	0.23	0.80	2.42	2.10	2.18	0.71	2.06	2.62	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).